
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is poised for growth with its diverse portfolio of radiopharmaceutical products that address unmet needs in the cardiology and oncology markets. The recent FDA approval of PYLARIFY TruVu, along with the upcoming PDUFA decision for MK6240, provide strong catalysts for future revenue growth. The company has a solid commercial footprint and utilizes strategic partnerships to enhance its portfolio, positioning it for long-term success. Given its strong financial performance in the first quarter and a favorable market outlook, Lantheus Holdings has the potential to deliver strong returns for investors.
Bears say
Lantheus Holdings is a high-risk investment due to its heavy reliance on a single product, Pylarify, for revenue. Despite its recent revenue and earnings beat, the company faces declining prices and volumes for Pylarify and has yet to receive significant credit for its pipeline in the Alzheimer's diagnostic market. While it has multiple agents in development, commercialization is dependent on the availability of therapeutic agents, and any potential revenue contribution is still a few years out. Additionally, the company is facing patent litigation and has some upcoming PDUFA decisions, adding to its already high-risk profile.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares